PTN Palatin Technologies, Inc. Comm

0.33
+0  (3%)
Previous Close 0.32
Open 0.32
Price To book 0.00
Market Cap 45.52M
Shares 137,947,000
Volume 960,675
Short Ratio 3.56
Av. Daily Volume 2,226,690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Female sexual dysfunction (FSD)
Phase 2 planned for 1H 2017
PL-3994
Heart failure

Latest News

  1. Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
  2. Palatin Technologies To Present At The 29th Annual ROTH Conference
  3. AMAG and Palatin Announce Rekynda™ Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
  4. Palatin Technologies, Inc. :PTN-US: Earnings Analysis: Q2, 2017 By the Numbers
  5. PALATIN TECHNOLOGIES INC Financials
  6. PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
  7. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition
  8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
  9. Q2 2017 Palatin Technologies Inc Earnings Release - Before Market Open
  10. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  11. Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
  12. Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
  13. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  14. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  15. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  16. Why AMAG Pharmaceuticals, Inc. Is Falling Today
  17. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  18. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  19. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  20. How CytRx Corporation (CYTR) Stacks Up Against Its Peers

SEC Filings

  1. CT ORDER - Confidential treatment order 17667211
  2. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17602637
  3. 10-Q - Quarterly report (Sections 13 or 15(d)) 17593538
  4. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17587846
  5. 8-K - Current report 17584693
  6. 8-K - Current report 17570367
  7. 8-K - Current report 17515868
  8. 424B5 - Prospectus (Rule 424(b)(5)) 162029414
  9. 8-K - Current report 162029082
  10. 424B5 - Prospectus (Rule 424(b)(5)) 162025472